Cedric O’Gorman, MD

Although this trial of esmethadone did not meet its primary outcome, some secondary and post hoc outcomes were promising.

Altered glutamatergic neurotransmission has been implicated in the pathogenesis of depression. This phase 3 trial evaluated the efficacy and safety of AXS-05 (dextromethorphan-bupropion) in the treatment of major depressive...